However, there are three new FDA-approved agents for prostate cancer imaging that are now available, Axumin® ([18F]-anti-1-amino-3-[18F]-fluorocyclobutane-1-carboxylic acid, also known as FACBC, Blue Earth Diagnostics, Oxford, UK) and two agents that target prostate specific membrane antigen, PYLARIFY® ([18F]-piflufolastat, also called DCFPyL or Pyl, Lanheus/Progenics, Millerica, MA, USA) and LOCAMETZ® ([68Ga]-PSMA-11, PSMA-HBED-CC, gozetotide, Advanced Accelerator Applications, Millburn, NJ, USA). Here, FOLH1 is linked to prostate carcinoma.